Early recovery of leukocyte subsets is associated with progression-free survival in patients with inoperable stage III NSCLC after multimodal treatment: a prospective explorative study

Thomas P. Hofer; Alexander E. Nieto; Lukas Käsmann; Carolyn J. Pelikan; Julian Taugner; Saloni Mathur; Chukwuka Eze; Claus Belka; Farkhad Manapov; Elfriede Nößner

doi:10.1101/2023.11.16.23298143

Abstract

Background We explored the dynamic changes of major leukocyte subsets during definitive treatment of patients with inoperable stage III NSCLC lung cancer and correlated it to survival to identify subpopulations associated with maximal patient benefit.

Methods We analyzed peripheral blood of 20 patients, either treated with thoracic radiotherapy (RT), concurrent chemo-radiotherapy (cCRT), or cCRT with additional immune-checkpoint inhibition therapy. Blood samples were collected at 9 timepoints before, during, and up to 1 year post treatment and analyzed by multi-color flow cytometry. Statistical analysis was conducted for leukocyte subpopulations, IL-6, progression-free survival (PFS) and overall survival (OS).

Results Increase of absolute lymphocyte counts (ALC) after the end of RT until 6 months thereafter was a predictor of PFS. Baseline lymphocyte counts showed no significant correlation to PFS or OS. Early recovery of absolute counts (AC) at 3 weeks after RT, total CD3+ T-cells, and CD8+ cytotoxic T-cells distinguished those patients with favorable PFS (≥12 months) from all other patients. Discriminant analysis identified B-cells, neutrophil-lymphocyte-ratio (NLR), CD4+ T-helper-cells, and NK-cells as predictors of favorable PFS. High variability in IL-6 plasma concentration of consecutive measurements within 6 months after the end of RT correlated negatively with PFS.

Conclusion Our results suggest that two parameters commonly assessed in clinical routine, can be used to predict patient outcome. These are: early increase in CD8+ T-cell lymphocyte-count and variability in IL-6 plasma concentration, that are correlated to patients with favorable, respectively, poor outcome after definitive therapy independent of treatment regimen.

Highlights

Early increase within 3 weeks after thoracic radiation therapy (TRT) of CD8+ T cells is associated with favorable progression free survival (PFS).
Low standard deviation in IL-6 plasma concentration in consecutive measurements after TRT is associated with favorable PFS.
Absolute lymphocyte counts at treatment begin had no predictive value for treatment outcome.

Funding statement none

Competing Interest Statement

Lukas Kaesmann reports a relationship with AstraZeneca that includes: funding grants. Lukas Kaesmann reports a relationship with Amgen Europe GmbH that includes: speaking and lecture fees. Claus Belka reports a relationship with Brainlab AG that includes: funding grants. Claus Belka reports a relationship with Elekta that includes: funding grants. Claus Belka reports a relationship with ViewRay Inc that includes: consulting or advisory, funding grants, speaking and lecture fees, and travel reimbursement. Claus Belka reports a relationship with Bristol Myers Squibb Co that includes: consulting or advisory, speaking and lecture fees, and travel reimbursement. Claus Belka reports a relationship with Roche that includes: consulting or advisory, speaking and lecture fees, and travel reimbursement. Claus Belka reports a relationship with Merck & Co Inc that includes: consulting or advisory, speaking and lecture fees, and travel reimbursement. Claus Belka reports a relationship with AstraZeneca that includes: consulting or advisory, speaking and lecture fees, and travel reimbursement. Claus Belka reports a relationship with European SocieTy for Radiotherapy and Oncology that includes: board membership. Farkhad Manapov reports a relationship with AstraZeneca that includes: board membership, funding grants, and speaking and lecture fees. Farkhad Manapov reports a relationship with Novartis that includes: board membership and speaking and lecture fees. Farkhad Manapov reports a relationship with Roche that includes: speaking and lecture fees. Farkhad Manapov reports a relationship with Eli Lilly and Company that includes: speaking and lecture fees. Farkhad Manapov reports a relationship with Elekta that includes: speaking and lecture fees. Farkhad Manapov reports a relationship with Brainlab AG that includes: speaking and lecture fees.

Funding Statement

This study did not receive any funding.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Ethics committee of the Ludwig-Maximilians-University of Munich gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes